NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)

Inclusion Criteria: * Women aged ≥ 18 years at the time of screening. * Patient has pathologically documented: * Primary advanced (FIGO III and IV) epithelial EC OR * Recurrent disease that is unlikely to be cured and where the multidisciplinary tumor board decision is systemic therapy. Carcinosarcomas are allowed, * Patient is intended or initiated to receive 1L CPD followed by maintenance therapy with durvalumab (dMMR cohort) or with durvalumab and olaparib (pMMR cohort) according to the SmPC of IMFINZI® and Lynparza®\* prior to enrollment. Recruitment of patients that already started and may have received up to 2 cycles of CPD is allowed but will be capped to 25% for each cohort of the study population. * Patient is eligible for treatment with durvalumab and/or olaparib as specified in the IMFINZI® and Lynparza® SmPC. The prescription of the medicinal product is clearly separated from the decision to include the patient in the study. * MMR-testing results of the patient's tumor are known. * Patient is willing and able to complete PRO questionnaires. * Patient can read and understand German, English, Arab, Russian or Turkish. * Signed written informed consent. Exclusion Criteria: * Patient has already received \>2 cycles of 1L CPD * Known hypersensitivity to carboplatin, paclitaxel, durvalumab and/or olaparib or any of the excipients of the drug. * Pregnancy or breast-feeding. * Unable to swallow orally administered medication. * Current or planned participation in an interventional clinical trial. * Current or planned systemic treatment of any tumor other than primary advanced or recurrent EC. * Patient has pathologically documented sarcoma

Reproduced word-for-word from the public registry record — the study team can answer questions about it.